AP3536A - Method of treating atrial fibrillation - Google Patents

Method of treating atrial fibrillation

Info

Publication number
AP3536A
AP3536A AP2012006331A AP2012006331A AP3536A AP 3536 A AP3536 A AP 3536A AP 2012006331 A AP2012006331 A AP 2012006331A AP 2012006331 A AP2012006331 A AP 2012006331A AP 3536 A AP3536 A AP 3536A
Authority
AP
ARIPO
Prior art keywords
atrial fibrillation
treating atrial
treating
fibrillation
atrial
Prior art date
Application number
AP2012006331A
Other languages
English (en)
Other versions
AP2012006331A0 (en
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2012006331A0 publication Critical patent/AP2012006331A0/xx
Application granted granted Critical
Publication of AP3536A publication Critical patent/AP3536A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2012006331A 2009-12-21 2010-12-20 Method of treating atrial fibrillation AP3536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (2)

Publication Number Publication Date
AP2012006331A0 AP2012006331A0 (en) 2012-06-30
AP3536A true AP3536A (en) 2016-01-13

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006331A AP3536A (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Country Status (37)

Country Link
US (3) US8513254B2 (xx)
EP (2) EP2749282B1 (xx)
JP (2) JP5723889B2 (xx)
KR (2) KR20160108611A (xx)
CN (3) CN102665713B (xx)
AP (1) AP3536A (xx)
AR (1) AR079552A1 (xx)
AU (1) AU2010339753B2 (xx)
BR (1) BR112012015499A2 (xx)
CA (1) CA2784028C (xx)
CL (1) CL2012001597A1 (xx)
CR (1) CR20120353A (xx)
CY (1) CY1116511T1 (xx)
DK (1) DK2515900T3 (xx)
EA (2) EA201691336A1 (xx)
EC (1) ECSP12012004A (xx)
ES (2) ES2646603T3 (xx)
HK (1) HK1170675A1 (xx)
HR (1) HRP20150644T1 (xx)
HU (1) HUE026916T2 (xx)
IL (1) IL220152A (xx)
ME (1) ME02179B (xx)
MX (2) MX2012007052A (xx)
NO (1) NO2749282T3 (xx)
NZ (2) NZ627181A (xx)
PE (1) PE20121520A1 (xx)
PL (2) PL2749282T3 (xx)
PT (2) PT2515900E (xx)
RS (1) RS54118B1 (xx)
SG (3) SG10201710751TA (xx)
SI (2) SI2749282T1 (xx)
SM (1) SMT201500171B (xx)
TW (1) TWI508726B (xx)
UA (1) UA109887C2 (xx)
UY (1) UY33119A (xx)
WO (1) WO2011084733A1 (xx)
ZA (1) ZA201204608B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486712C (en) 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
CA2768985C (en) 2009-07-29 2020-03-10 Icu Medical, Inc. Fluid transfer devices and methods of use
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
NO3175985T3 (xx) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NZ627942A (en) * 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
WO2015017441A1 (en) * 2013-08-02 2015-02-05 Gilead Sciences, Inc. Pharmaceutical compositions of ranolazine and dronedarone
EP3068440B1 (en) * 2013-11-15 2020-01-08 Northwestern University Inhibition of oxidative stress in atrial fibrillation
SG11201604457XA (en) 2013-12-19 2016-07-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP3423057A1 (en) 2016-03-04 2019-01-09 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
CN113993551A (zh) * 2019-01-24 2022-01-28 西北大学 心房颤动的基因疗法治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150535A1 (en) * 2008-06-10 2009-12-17 Sanofi-Aventis Dronedarone for the prevention of permanent atrial fibrillation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE69033967T2 (de) 1989-06-23 2002-12-19 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
DE60127410T2 (de) 2000-07-27 2007-12-13 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US20050065208A1 (en) 2001-07-20 2005-03-24 Bodo Brandts Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
AU2006203890A1 (en) 2005-01-06 2006-07-13 Gilead Sciences, Inc. Sustained release pharmaceutical formulations comprising ranolazine
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP2136780A1 (en) 2007-02-13 2009-12-30 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
WO2010028173A2 (en) 2008-09-04 2010-03-11 Gilead Palo Alto, Inc. Method of treating atrial fibrillation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150535A1 (en) * 2008-06-10 2009-12-17 Sanofi-Aventis Dronedarone for the prevention of permanent atrial fibrillation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTZELEVITCH C. et al., "Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation", Journal of Electrocardiology, 1 November 2009, Vol. 42, No. 6, pages 543-548 *
FOR THE ERATO STUDY INVESTIGATORS ET AL: "Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study", AMERICAN HEART JOURNAL, vol. 156, no. 3, September 2008 (2008-09-01), MOSBY- YEAR BOOK INC, US, pages 527.E1 - 527.E9, XP025470440 *
GRAMLEY FELIX ET AL: "Recent advances in the pharmacological treatment of cardiac arrythmias.", DRUGS OF TODAY, vol. 45, no. 11, November 2009 (2009-11-01), BARCELONA, SPAIN, pages 807 - 824, XP002631257 *
KUMAR KAPIL ET AL: "New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future.", CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, vol. 11, no. 5, October 2009 (2009-10-01), pages 373 - 380, XP002631255 *
SCIRICA BENJAMIN M ET AL: "Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of Arrhythmias in patients with Non-ST-Segment-Elevation acute coronary syndrome - Thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Randomized controlled trial", CIRCULATION, vol. 116, no. 15, October 2007 (2007-10-01), pages 1647 - 1652, XP002631256 *

Also Published As

Publication number Publication date
JP5723889B2 (ja) 2015-05-27
CA2784028C (en) 2016-08-23
ME02179B (me) 2015-10-20
AU2010339753B2 (en) 2015-01-22
CN102665713B (zh) 2015-02-18
CN104147010A (zh) 2014-11-19
NZ627181A (en) 2016-02-26
IL220152A (en) 2016-11-30
RS54118B1 (en) 2015-12-31
ES2646603T3 (es) 2017-12-14
SI2749282T1 (sl) 2017-12-29
EA201290451A1 (ru) 2013-01-30
EP2515900B1 (en) 2015-04-29
CR20120353A (es) 2014-10-07
NO2749282T3 (xx) 2018-01-06
EP2515900A1 (en) 2012-10-31
DK2515900T3 (en) 2015-07-27
US20140323493A1 (en) 2014-10-30
UA109887C2 (uk) 2015-10-26
MX344329B (es) 2016-12-13
EP2749282A1 (en) 2014-07-02
JP2015057449A (ja) 2015-03-26
PL2515900T3 (pl) 2015-10-30
CN102665713A (zh) 2012-09-12
EA201691336A1 (ru) 2017-05-31
TW201136586A (en) 2011-11-01
BR112012015499A2 (pt) 2016-05-03
HRP20150644T1 (hr) 2015-07-31
ZA201204608B (en) 2013-02-27
AR079552A1 (es) 2012-02-01
PL2749282T3 (pl) 2018-01-31
SG181541A1 (en) 2012-07-30
US20130317038A1 (en) 2013-11-28
AP2012006331A0 (en) 2012-06-30
CN104688739A (zh) 2015-06-10
EA025445B1 (ru) 2016-12-30
EP2749282B1 (en) 2017-08-09
SMT201500171B (it) 2015-09-07
SI2515900T1 (sl) 2015-07-31
HUE026916T2 (en) 2016-08-29
WO2011084733A1 (en) 2011-07-14
PT2749282T (pt) 2017-11-15
KR20120107995A (ko) 2012-10-04
NZ600718A (en) 2014-08-29
JP2013515007A (ja) 2013-05-02
AU2010339753A1 (en) 2012-07-12
US20110183990A1 (en) 2011-07-28
TWI508726B (zh) 2015-11-21
SG10201710751TA (en) 2018-02-27
MX2012007052A (es) 2012-07-30
UY33119A (es) 2011-07-29
US8513254B2 (en) 2013-08-20
SG10201408528RA (en) 2015-04-29
PT2515900E (pt) 2015-07-30
ES2540093T3 (es) 2015-07-08
IL220152A0 (en) 2012-07-31
CY1116511T1 (el) 2017-03-15
HK1170675A1 (en) 2013-03-08
US9056108B2 (en) 2015-06-16
CL2012001597A1 (es) 2013-06-28
ECSP12012004A (es) 2012-08-31
KR20160108611A (ko) 2016-09-19
US8754087B2 (en) 2014-06-17
CA2784028A1 (en) 2011-07-14
PE20121520A1 (es) 2012-11-26

Similar Documents

Publication Publication Date Title
AP3536A (en) Method of treating atrial fibrillation
EP2558014A4 (en) Methods and devices for treating atrial fibrillation
EP2421607A4 (en) DEVICE AND METHOD FOR PROOFING AND TREATING PREVIOUS LAYOUMS
IL208354A0 (en) Methods of treatment
HK1254495A1 (zh) 舒巴林用於治療心房纖顫的用途
IL214664A0 (en) Methods of treating hair related conditions
EP2350641A4 (en) Methods of Treatment
GB201018147D0 (en) Method of treatment
GB201003920D0 (en) Method of treatment
EP2473232A4 (en) METHOD AND DEVICE FOR TREATING HEART RADIATOR DISORDERS
ZA201108493B (en) Method of treating hair
ZA201005206B (en) Method of treating hair
IL216456A0 (en) Method of treating frailty
EP2585103A4 (en) METHOD OF TREATMENT
GB201018149D0 (en) Method of treatment
HK1204262A1 (en) Method of treating atrial fibrillation
GB201020015D0 (en) Method of treatment
AU2011904917A0 (en) Method for preventing and/or treating atrial fibrillation
GB0823435D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0900624D0 (en) Method of treating wool
GB201005071D0 (en) Method of treatment
GB201003917D0 (en) Method of treatment